Anisakis pegreffii is a parasitic nematode that infects a variety of marine hosts, including fish, squid, and marine mammals, such as seals and dolphins. When humans consume raw or undercooked seafood that is infected with A. pegreffii, they can develop a condition known as anisakiasis, which can cause abdominal pain, nausea, and vomiting.

The cytochrome c oxidase subunit 2 (COX2) gene have been used to identify and classify different Anisakis species, including A. pegreffii. COX2 is a mitochondrial gene that plays an important role in cellular respiration, and its sequence can be used to distinguish between different species of nematodes. This method has been used in studies to determine the prevalence and distribution of different Anisakis species, and to understand the patterns of host-parasite interactions.

The study of Anisakis pegreffii and its association with COX2 is important for understanding the biology and ecology of this parasite, as well as for developing strategies to prevent and treat anisakiasis in humans. Anisakiasis is a growing public health concern, especially in areas where raw or undercooked seafood is commonly consumed. Efforts to control the spread of Anisakis infections and to educate the public about the risks of consuming raw or undercooked seafood are ongoing.

Overall, understanding the relationship between Anisakis pegreffii and its host species, as well as the role of COX2 in the biology and evolution of this parasite, has important implications for human health and the health of marine ecosystems.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.